ABTOverviewFundamentalsDividendsTechnicalsRiskCatalystsNewsFinancial DataAIQ Pro
Current stock page

Catalysts

ABT Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - DevicesScore data as of Oct 30, 2026

ABTAbbott Laboratories

Healthcare / Medical - Devices

Low Priority

Above Peers

NeutralEdge 7/10
$106.20+$1.63 (+1.56%)

Latest quote

  • Momentum
    74
  • Value
    51
  • Quality
    55
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Oct 30, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Jan 28, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 59/100

Momentum 74/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Oct 30, 2026 · Sentiment 44.07%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 74/100AIQ Edge 7/10 Above Peers
Beat rate
40%
2 of 5 reported periods
Average surprise
+0.6%
Across covered historical reports
Latest result
+0.0%
Oct 21, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 21, 2026—$1.42$1.42+0.0%$12.99B$13.01B
Jul 16, 2026—$1.28$1.31+2.3%$12.52B$12.59B
Apr 16, 2026—$1.14$1.15+0.9%$11B$11.16B
Jan 22, 2026—$1.50$1.50+0.0%$11.8B$11.46B
Oct 15, 2025—$1.30$1.30+0.0%$11.39B$11.37B
Read the ABT earnings call analysisEarnings calendar, results and surprises

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
24
Buy
5
Hold
12-month analyst target
$122.27
+15.13% versus current price
Based on 11 analyst observations. Targets are estimates, not predictions.
Low target
$112.00
+5.46% vs latest price
Average target
$122.27
+15.13% vs latest price
High target
$134.00
+26.18% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateJan 28, 2027

Next known earnings or reporting date.

EPS estimate$1.64

Current analyst expectation for the upcoming report.

Revenue estimate$13.22B

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score74

Where event reaction would show up first.

AIQ score59/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
11
Average target
$122.27
Target upside
15.13%
Target range
$112.00 - $134.00
90-day revisions
-4

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
0
economictimes.indiatimes.com · Oct 28, 2026

quantum computing chips: German startup NVision shows new path to quantum computing chips in Nature paper

Startups and tech giants such as Microsoft and IBM alike are racing to build quantum computers that hold the promise of solving problems that would take conventional machines thousands of years. But NVision, which has raised more than $155 million in funding from firms such as Abbott Laboratories, made the discovery published on Wednesday while working in an entirely different field: improving medical devices.

gurufocus.com · Oct 27, 2026

ABT Downgraded by Argus Research -- Rating Changed to Hold

Abbott Laboratories (ABT) Analyst Rating Update On October 23, 2026, Abbott Laboratories (ABT) received a downgrade from Argus Research, shifting its rating

gurufocus.com · Oct 27, 2026

Is ABT Overvalued? DCF Says Worth $86

On October 27, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year in the market, with its stock pric

zacks.com · Oct 27, 2026

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Open full news and sentiment

Related Links

ABT Catalysts FAQ

What are the next catalysts for ABT stock?

ABT's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ABT stock?

Upcoming events that could move ABT include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ABT's next earnings report affect the stock?

ABT's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ABT stock higher?

ABT could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ABT stock?

ABT could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.